RT Journal Article
SR Electronic
T1 Role of [<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1994
OP 2003
DO 10.1111/j.1525-1438.2006.00729.x
VO 16
IS 6
A1 Lin, C.-T.
A1 Yen, T.-C.
A1 Chang, T.-C.
A1 Ng, K.-K.
A1 Tsai, C.-S.
A1 Ho, K.-C.
A1 Lai, C.-H.
YR 2006
UL http://ijgc.bmj.com/content/16/6/1994.abstract
AB Cervical cancer patients with histologically documented re-recurrence after curative salvage therapy or unexplained tumor marker elevation (negative computed tomography and/or magnetic resonance imaging [CT-MRI]) proven to be a re-recurrence when a further attempt for cure (or control of cancer) appeared feasible were enrolled. Lesion status was determined from pathology or clinical follow-up for at least 12 months. Management decisions were recorded with CT-MRI alone and incorporating [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), respectively. The benefits calculated were based on clinical impact because of the FDG-PET findings. Cox proportional hazards model was used to select independent prognostic covariates. Of the 26 patients who were eligible for analysis, 12 (46.2%) patients had positive impacts due to PET. Squamous cell carcinoma (SCC, P= 0.029), re-recurrence at distant metastasis only (P= 0.012), and level of SCC antigen ≤4 ng/mL (P= 0.005) were significantly associated with better survival. A scoring system using these covariates defined three distinct prognostic groups (P= 0.0001). Patients with score 0 had a 36-month cumulative survival rate of 80%. Using this prognostic scoring system, FDG-PET may facilitate selecting appropriate management for the individual patient with re-recurrent cervical cancer.